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Introduction
Autotaxin (ATX, ENPP2) is responsible for the production of the bioactive lipid lysophosphatidic acid (LPA) from lysophospholipids which exist extracellularly, primarily derived from lysophosphatidylcholine (LPC). 1 The product of this process, LPA, is an agonist of six G protein-coupled receptors that drives a range of signaling pathways. 2 This action produces a broad range of biological outcomes, and the pathophysiology of ATX has been associated with pulmonary fibrosis, tumor progression, cardiovascular disease, neuropathic pain, and cholestatic pruritus; these functions make the ATX-LPA signaling pathway an attractive prospect from the point of view of therapeutic intervention. 3 The catalytic domain of the enzyme consists of an active site containing to zinc ions in proximity to a catalytic threonine. The endogenous ligand (LPC) binds in a shallow hydrophilic groove that is capable of accommodating both nucleotides as well as the glycerol motif of lysophospholipids. There also exists a relatively deep hydrophobic pocket which is responsible for binding of the lysophospholipid acyl chain. The catalytic domain in conjunction with the first of two somatomedin-(SMB) domains, constitutes a tunnel adjacent to the active site. [4] [5] Recently, we reported that ATX produced in mammalian cells contains steroids bound within the tunnel region. During that study, we determined the structures of natural endogenous steroids bound to the ATX tunnel, including that of tauroursodeoxycholic acid (TUDCA, 1, Figure 1 ), a micromolar inhibitor of LPA production.
We demonstrated that binding of bile salts, allosterically modulates ATX activity through non-competitive inhibition, likely having physiologically important implications for the function of the ATX-mediated signaling through LPA receptors in a number of pathophysiological contexts. 6 The majority of small molecule inhibitors of ATX developed to date emulate the lipid-like structure of the native ligand and bind in the orthosteric site (e.g. 3, Figure 1 ). By contrast, a recent series of indole-based ATX inhibitors 7 and the lead compound of an independent discovery program 8 are reported to occupy the hydrophobic pocket and tunnel, without interacting with the hydrophilic groove or the active site, acting as allosteric inhibitors, similar to natural bile salts.
In this manuscript, we formulate a design hypothesis based on structural knowledge of the binding mode of the partial non-competitive allosteric inhibitor bile salts, and competitive orthosteric inhibitors. 9 Specifically, we used the structure of compound 1 bound to ATX ( Figure 1 ) which we recently determined binding in the allosteric tunnel region, 6 and the structure of a compound from the represented by compound 2 (PF-8380), 10 which we had determined in complex with ATX, showing the binding of this chemotype in the orthosteric site.
From consideration of these binding modes we inferred that the tunnel-binding steroid skeleton could be merged with the lipophilic pocket-binding "tail" of compound 2. While the
Figure 2. Overarching design hypothesis
These compounds could be rapidly prepared through HATU-mediated amide bond formation between ursodeoxycholic acid (UDCA) and appropriate amine fragments (Scheme 1).
Compound 11 was accessed through reduction of the amide to give the corresponding amine derivative. The requisite amine components could be prepared through carbamate formation on the mono-protected diamine, followed by deprotection to furnish the free amine as represented by the example shown in Scheme 2. To our delight, the first hybrid compound prepared (4 , Table 1 ) showed approximately an 80-fold increase in potency relative to the progenitor bile acid (0.1β9 M compared to 10 M, determined through measurement of inhibition of LPC hydrolysis), confirming that the concept of maintaining the steroid moiety while also targeting the hydrophobic pocket of ATX had indeed increased inhibitor potency. In agreement with this hypothesis, compounds without chlorine substituents (9-10) or lacking a hydrophobic anchor entirely (8) in this initial set of analogues, results in no detectable inhibitory activity. These findings are consistent with SAR previously established for the hydrophobic pocket, all of which indicate a degree of lipophilicity in this region is required for adequate levels of ATX-inhibitory activity. [10] [11] [12] [13] In this initial survey of SAR, we also sought to examine the length and nature of the linker (5-7). While the piperazine unit in 4 was optimal, linear systems exhibit only slightly lower potency (5-6); however, a very short spacer (7) resulted in no detectable inhibitory activity.
Compound 11, lacking the amide carbonyl of 4, had five-fold lower potency. To further rationalize the SAR data obtained and confirm our proposed binding mode hypothesis, we determined the crystal structure of ATX bound to 5 and 11 to 2.4 Å and 2.1 Å resolution, respectively (Figure 3 A-D and Figure 4 A and B). These structures fully support our original design hypothesis and demonstrate that the hydrophobic anchor, the 3,5-dichlorobenzyl group, occupies essentially the same position in the hydrophobic pocket in the structures of 3, 5, and 11. Notably, the steroid moiety also remains in a similar, albeit not identical binding orientation between structures, when comparing the structures of 1, 5, and 11, and is held in position by several interactions including two hydrogen bonds, with the Tyr82 and Trp260 side chains. The piperazine linker unit, however, adopts a significantly different conformation in 11 compared to 3, projecting towards the tunnel, instead of the catalytic site; the linear linker in 5 follows a similar vector to that of the piperazine in 11.
Interestingly, the linker region in both structures does not exhibit well defined electron density compared to the other groups, suggesting a certain degree of structural flexibility in the region, with the linker potentially adopting several conformations. Accordingly, these structures suggest that the bile salt steroid moiety and the dichlorobenzyl group act as anchors in the tunnel and the pocket, respectively, and optimization of binding should subsequently focus on the linker region to provide a conformation which may lead to optimal binding. Based on this, the 3,5-dichlorobenzyl group was retained in subsequent analogues prepared, and our focus turned to tuning the spacer region of our nascent series.
Several isosteric cores were evaluated (12-20, Table 1 ) with a range of ATX inhibitory activity noted. Aminomethyl piperidine systems were tolerated with a preference for the exocyclic carbamate (cf. 12-13), and more constrained systems such as 14 led to a 10-fold reduction in activity. Other isosteres such as azetidinyl and 3-amino pyrrolidine (15) (16) (17) (18) (19) (20) showed comparable levels of potency relative to the progenitor compound 4. A notable exception is evidenced by compound 17, displaying an IC50 of 20 nM against ATX mediated production of LPA, which compares favorably to 2 (IC50 = 3 nM 10 ). Additionally, This represents an over 500-fold improvement in activity compared to the parent bile acid, and demonstrates the utility of a structure based design approach in expediently optimizing a weak endogenous modulator of ATX activity towards a highly potent lead candidate. Lastly, in order to examine inhibition of ATX in vivo, 17, and 2 as a positive control, were administered to mice (10 mg/kg, i.p.) and the levels of eight abundant LPA species were summed and determined by mass spectrometry. 15 The in vivo activity of 17 was similar to that of 2, reducing LPA levels to about half to that of control mice injected with vehicle alone (Figure 6 B In summary, we report the development of an endogenous steroid modulator of Autotaxin function towards a highly potent hybrid lead series with significant levels of activity in vivo.
The optimization trajectory was significantly expedited through application of a structurebased design approach, leading to the rapid identification of compound 17 which could be differentiated from the progenitor steroid both in terms of significantly enhanced potency and mechanism of action (competitive vs non-competitive inhibition of LPA hydrolysis). The structural data generated confirmed the original design hypothesis, and support the observed mechanism of action for the series lead, compound 17. Inhibition of ATX activity by our lead compound in cells and in a pilot experiment in mice, suggest that these new entities will serve as valuable tools in further understanding the pathophysiological roles of Autotaxin.
Experimental
Chemistry. General. All reagents and solvents were obtained from commercial suppliers and were used without further purification unless otherwise stated. Purification was carried out according to standard laboratory methods. Reactions were carried out using conventional glassware room temperature was generally 18 °C. Reactions were carried out at elevated temperatures using a temperature-regulated hotplate/stirrer. Thin layer chromatography was carried out using Merck silica plates coated with fluorescent indicator UV254. These were analyzed under 254 nm UV light or developed using potassium The crude material was subjected to the purification outlined in the General Procedure (silica gel, 0-10% MeOH in CH2Cl2) to afford the desired product as a clear solid (258 mg, 37%). to afford the desired product as a white solid (4 mg, 4% 1-((4R)-4-((3R,7S,10S,13R) 1-((4R)-4-((3R,7S,10S,13R) Protein production and crystallization. ATX from rat was produced in HEK293 Flp-In cells as described previously. 16 For co-crystallization of rATX with 3, 11, 5, and 17, rATX (3.5 mg Crystallographic data and methods. The X-ray diffraction data for the ATX-inhibitor complexes were collected at SLS on beamlines PXIII (3, 11, and 5) and PXI (17) at 100K.
Benzyl (2-((4R)-4-((3R
,
Benzyl-4-((4R)-4-((3R
3,5-Dichlorobenzyl-4-((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-

3,5-Dichlorobenzyl-4-(((4R)-4-((3R,7S,10S,13R)-3,7-dihydroxy-
2-(3,5-Dichlorobenzyl)-7-((4R)-4-((3R
The crystallographic diffraction data for the ATX-inhibitor complexes were recorded on a PILATUS 2M-F detector for 3, 11, and 5 to a resolution of 1.95, 2.4, and 2.1 Å, respectively and on the EIGER 16M detector for 17 to 2.1 Å. All data were processed and integrated with XDS. 17 17 was processed on site using the SLS automated processing pipeline and scaled with AIMLESS. 18 The structures were determined by molecular replacement using PHASER 19 with the structure of ATX (PDB entry 2XR9) as the search model. Model building and subsequent refinement were performed iteratively with COOT 20 REFMAC5 21 and PDB_REDO. 22 Structure validation was carried out by MolProbity. The structure models and experimental diffraction data were deposited at the PDB under codes 5MOS, 5MOM, 5MOD, 5MOE). Crystallographic data and refinement details are available in Table 2 . Biochemical assays and modeling of kinetic data. ATX lysoPLD activity was measured by choline release from LPC. 23 
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